Age-related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

Age-related Macular Degeneration Treatment Market

(Albany, USA) DelveInsight’s ‘Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast–2034’ report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Age-related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Age-related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Age-related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Age-related Macular Degeneration market.

Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular Degeneration Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Macular Degeneration Market Size

Key Takeaways from the Age-related Macular Degeneration Market Report

• The Age-related Macular Degeneration market size in seven major markets is segregated into two part, Dry-AMD, and Wet-AMD. As per our analysis and estimation, in 2021, the Age-related Macular Degeneration market size was approximately USD 9,840 million which is further expected to increase by 2034.
• In April 2025, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept, in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).
• In December 2024, Galimedix Therapeutics announced the initiation of its Phase II eDREAM study to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration.
• In December 2024, Ocugen, Inc. announced that the Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study. OCU410 (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
• In October 2024, Eyestem Research, focused on creating scalable cell therapies for incurable diseases, had announced a positive outcome of the Drug Safety Monitoring Board (DSMB) review for the first cohort of its Phase one trial to treat Geographic Atrophy secondary to Dry Age-related Macular Degeneration, marking a milestone for Indian science and medical research.
• In September 2024, Stealth BioTherapeutics Inc. announced the presentation of new bevemipretide (SBT-272) preclinical data demonstrating topical ocular delivery to the retina with protective effects observed in models of AMD.
• June 2024:- Stealth BioTherapeutics Inc.- A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD).
• June 2024:- Outlook Therapeutics Inc- Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
• In the year 2022, the total prevalent cases of AMD were approximately 52,684,880 in the 7MM, which might increase at a decent CAGR by 2034.
• The US accounted for approximately 17,688,550 prevalent cases of AMD in the year 2022.
• The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
• Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.

Delve deep into the Age-related Macular Degeneration Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Macular Degeneration Market Forecast. Click here to shape the future @ Age-related Macular Degeneration Prevalence

Age-related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a common eye condition and a leading cause of vision loss in adults aged 50 and older. It affects the macula, the central part of the retina responsible for sharp, detailed vision needed for activities like reading, driving, and recognizing faces. AMD is classified into two types: dry (atrophic) and wet (neovascular).

Dry AMD, the more common form, occurs due to the gradual breakdown of macular cells, leading to blurry or distorted central vision. It often progresses slowly and may remain asymptomatic in the early stages. Wet AMD is less common but more severe, involving the growth of abnormal blood vessels under the retina that leak fluid or blood, causing rapid vision loss.

Symptoms of AMD include blurry central vision, difficulty seeing in low light, distorted lines, or a dark, empty area in the center of vision. Risk factors include aging, genetic predisposition, smoking, obesity, and high blood pressure.

While there is no cure, treatments aim to slow progression. For dry AMD, lifestyle modifications like a healthy diet rich in antioxidants and omega-3 fatty acids are recommended. Wet AMD may require anti-VEGF injections, laser therapy, or photodynamic therapy. Regular eye exams are essential for early detection and management.

Age-related Macular Degeneration Epidemiology Insights

• Total Age-related Macular Degeneration Prevalent Cases • Total Age-related Macular Degeneration Age-specific Cases • Total Age-related Macular Degeneration Diagnosed Prevalent Cases • Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages • Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment • Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

Navigate the complexities of the Age-related Macular Degeneration Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Macular Degeneration Market Forecast. Click here to get more insights @ Age-related Macular Degeneration Treatment Markets

Age-related Macular Degeneration Market Insights

Age-related Macular Degeneration is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss.

Age-related Macular Degeneration Treatment Landscape

The best available treatment for AMD was photodynamic therapy—in which an intravenous drug (injected into a vein) and laser were used to seal off leaking blood vessels. Past studies have found that just 1 year after diagnosis, less than 15% of patients given this therapy alone retain 20/40 vision, and up to 40% decline to 20/200 vision. However, advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function.

Age-related Macular Degeneration Market Size

According to the DelveInsight analysis, the United States accounted for the highest market size, with approximately 50% of the market share of Dry age-related Macular Degeneration (AMD) as compared to other countries of the 7MM in the year 2022. The Age-related Macular Degeneration market size of the 7MM is anticipated to increase in the forecast period due to expected launch of emerging therapies in the 7MM.

Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Macular Degeneration Market Forecast. Click here @ Age-related Macular Degeneration Market Drivers and Barriers

Age-related Macular Degeneration Therapies and Companies

• Eylea (aflibercept): Regeneron Pharmaceuticals
• Beovu(brolucizumab): Novartis
• Lucentis (ranibizumab): Roche
• Vabysmo (faricimab): Roche
• Susvimo (ranibizumab): Roche

Age-related Macular Degeneration Drug Market

The overall Age-related Macular Degeneration (AMD) Market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2024–2034).

Scope of the Age-related Macular Degeneration Market Report

• Coverage- 7MM
• Age-related Macular Degeneration Companies- Unity Biotechnology, Inc. (NASDAQ: UBX), PanOptica, Inc. (Private), Clearside Biomedical (NASDAQ: CLSD), Alexion Pharmaceuticals (NASDAQ: ALXN), AstraZeneca (NASDAQ: AZN), Regeneron Pharmaceuticals (NASDAQ: REGN), Novartis (SWX: NOVN), Roche (SWX: ROG), Opthea Limited (ASX: OPT), Kodiak Sciences Inc. (NASDAQ: KOD), REGENXBIO (NASDAQ: RGNX), Alkahest Inc. (Private), Graybug Vision (NASDAQ: GRAY), Ribomic USA Inc. (TSE: 4591), Outlook Therapeutics, Inc. (NASDAQ: OTLK), Evergreen Therapeutics (Private), Alkeus Pharmaceuticals (Private), Stealth BioTherapeutics (NASDAQ: MITO), CellCure Neurosciences (Private), Regenerative Patch Technologies (Private), Allegro Ophthalmics (Private), Annexon Biosciences (NASDAQ: ANNX), NGM Biopharmaceuticals (NASDAQ: NGM), Ionis Pharmaceuticals (NASDAQ: IONS), Apellis Pharmaceuticals (NASDAQ: APLS), Iveric Bio (NASDAQ: ISEE), Gyroscope Therapeutics (Private), Luxa Biotechnology (Private), Gemini Therapeutics (NASDAQ: GMTX), and others.
• Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
• Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Age-related Macular Degeneration Market Access and Reimbursement

Gain a strategic edge in the Age-related Macular Degeneration Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Macular Degeneration Market Forecast. Click here to lead in advancements @ Age-related Macular Degeneration Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders’ Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services